Comments
Loading...
Syros Pharmaceuticals Analyst Ratings and Price Targets | OTC:SYRS | Benzinga
Syros Pharmaceuticals Inc has a consensus price target of $7.25 based on the ratings of 7 analysts. The high is $13 issued by Oppenheimer on March 3, 2023. The low is $1 issued by HC Wainwright & Co. on November 13, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and JMP Securities on November 13, 2024, November 1, 2024, and August 13, 2024, respectively. With an average price target of $3.67 between HC Wainwright & Co., HC Wainwright & Co., and JMP Securities, there's an implied 17873.86% upside for Syros Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
Oppenheimer
Alliance Global Partners
1calculated from analyst ratings
Analyst Ratings for Syros Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 11/13/2024 | Buy Now | — | TD Cowen | Phil Nadeau66% | — | Downgrade | Buy → Hold | Get Alert |
| 11/13/2024 | Buy Now | 4801.96% | HC Wainwright & Co. | Andrew Fein54% | $6 → $1 | Downgrade | Buy → Neutral | Get Alert |
| 11/13/2024 | Buy Now | — | JMP Securities | Jason Butler51% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 11/13/2024 | Buy Now | — | Brookline Capital | Leah Rush58% | — | Downgrade | Buy → Hold | Get Alert |
| 11/01/2024 | Buy Now | 29311.76% | HC Wainwright & Co. | Andrew Fein54% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 19507.84% | JMP Securities | Jason Butler51% | $12 → $4 | Maintains | Market Outperform | Get Alert |
| 08/13/2024 | Buy Now | 24409.8% | Piper Sandler | Edward Tenthoff52% | $13 → $5 | Reiterates | Overweight → Overweight | Get Alert |
| 08/13/2024 | Buy Now | 29311.76% | HC Wainwright & Co. | Andrew Fein54% | $15 → $6 | Maintains | Buy | Get Alert |
| 08/01/2024 | Buy Now | 73429.41% | HC Wainwright & Co. | Andrew Fein54% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2024 | Buy Now | 73429.41% | HC Wainwright & Co. | Andrew Fein54% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 73429.41% | HC Wainwright & Co. | Andrew Fein54% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 63625.49% | Piper Sandler | Edward Tenthoff52% | → $13 | Reiterates | Overweight → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 73429.41% | HC Wainwright & Co. | Andrew Fein54% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2023 | Buy Now | 34213.73% | Piper Sandler | Edward Tenthoff52% | $11 → $7 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 73429.41% | HC Wainwright & Co. | Andrew Fein54% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 73429.41% | HC Wainwright & Co. | Andrew Fein54% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 73429.41% | JMP Securities | Jason Butler51% | $16 → $15 | Maintains | Market Outperform | Get Alert |
| 03/03/2023 | Buy Now | 63625.49% | Oppenheimer | Mark Breidenbach48% | $15 → $13 | Maintains | Outperform | Get Alert |
| 03/03/2023 | Buy Now | 73429.41% | HC Wainwright & Co. | Andrew Fein54% | → $15 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | Buy Now | 97939.22% | Piper Sandler | Edward Tenthoff52% | $27 → $20 | Maintains | Overweight | Get Alert |
| 11/15/2022 | Buy Now | 78331.37% | JMP Securities | Jason Butler51% | $40 → $16 | Maintains | Market Outperform | Get Alert |
| 11/15/2022 | Buy Now | 73429.41% | Oppenheimer | Mark Breidenbach48% | $30 → $15 | Maintains | Outperform | Get Alert |
| 11/15/2022 | Buy Now | 97939.22% | HC Wainwright & Co. | Andrew Fein54% | $6 → $20 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | 14605.88% | Oppenheimer | Mark Breidenbach48% | $90 → $30 | Maintains | Outperform | Get Alert |
| 07/12/2022 | Buy Now | 29311.76% | HC Wainwright & Co. | Andrew Fein54% | $100 → $60 | Maintains | Buy | Get Alert |
| 05/17/2022 | Buy Now | 48919.61% | HC Wainwright & Co. | Andrew Fein54% | $150 → $100 | Maintains | Buy | Get Alert |
| 05/17/2022 | Buy Now | 48919.61% | Alliance Global Partners | Matt Cross3% | $140 → $100 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Syros Pharmaceuticals (SYRS) stock?
The latest price target for Syros Pharmaceuticals (OTCPK:SYRS) was reported by TD Cowen on November 13, 2024. The analyst firm set a price target for $0.00 expecting SYRS to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Syros Pharmaceuticals (SYRS)?
The latest analyst rating for Syros Pharmaceuticals (OTCPK:SYRS) was provided by TD Cowen, and Syros Pharmaceuticals downgraded their hold rating.
When was the last upgrade for Syros Pharmaceuticals (SYRS)?
There is no last upgrade for Syros Pharmaceuticals
When was the last downgrade for Syros Pharmaceuticals (SYRS)?
The last downgrade for Syros Pharmaceuticals Inc happened on November 13, 2024 when TD Cowen changed their price target from N/A to N/A for Syros Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Syros Pharmaceuticals (SYRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syros Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syros Pharmaceuticals was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.
Is the Analyst Rating Syros Pharmaceuticals (SYRS) correct?
While ratings are subjective and will change, the latest Syros Pharmaceuticals (SYRS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Syros Pharmaceuticals (SYRS) is trading at is $0.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
